Glucose Metabolism In Skeletal Muscle Research Articles

Secreted protein acidic and rich in cysteine (SPARC) improves glucose tolerance via AMP-activated protein kinase activation.

During exercise, skeletal muscles release cytokines, peptides, and metabolites that exert autocrine, paracrine, or endocrine effects on glucose homeostasis. In this study, we investigated the effects of secreted protein acidic and rich in cysteine (SPARC), an exercise-responsive myokine, on glucose metabolism in human and mouse skeletal muscle. SPARC-knockout mice showed impaired systemic metabolism and reduced phosphorylation of AMPK and protein kinase B in skeletal muscle. Treatment of SPARC-knockout mice with recombinant SPARC improved glucose tolerance and concomitantly activated AMPK in skeletal muscle. These effects were dependent on AMPK-γ3 because SPARC treatment enhanced skeletal muscle glucose uptake in wild-type mice but not in AMPK-γ3-knockout mice. SPARC strongly interacted with the voltage-dependent calcium channel, and inhibition of calcium-dependent signaling prevented SPARC-induced AMPK phosphorylation in human and mouse myotubes. Finally, chronic SPARC treatment improved systemic glucose tolerance and AMPK signaling in skeletal muscle of high-fat diet-induced obese mice, highlighting the efficacy of SPARC treatment in the management of metabolic diseases. Thus, our findings suggest that SPARC treatment mimics the effects of exercise on glucose tolerance by enhancing AMPK-dependent glucose uptake in skeletal muscle.-Aoi, W., Hirano, N., Lassiter, D. G., Björnholm, M., Chibalin, A. V., Sakuma, K., Tanimura, Y., Mizushima, K., Takagi, T., Naito, Y., Zierath, J. R., Krook, A. Secreted protein acidic and rich in cysteine (SPARC) improves glucose tolerance via AMP-activated protein kinase activation.

294-LB: Transcriptome-Wide Signals Converge Upon Mitochondrial Function in Developmental Stages of Type 2 Diabetes in Human Skeletal Muscle

Skeletal muscle is a major contributor to overall glucose homeostasis in the body and together with the liver is chiefly responsible for the whole-body insulin sensitivity. However, few studies have investigated the transcriptional signature of insulin resistance in skeletal muscles, at different stages of T2D development. Thus, the aim of this study was to identify the transcriptional signature of dysregulated glucose metabolism in skeletal muscle in humans by profiling the transcriptome with next-generation sequencing (NGS). We selected 40 sedentary males, aged 40-65 years, with BMI 26-33 kg/m2, diagnosed into three groups: 18 normoglycemics, 14 prediabetics and 8 subjects with type 2 diabetes. mRNA was extracted from biopsied Vastus lateralis muscles and sequenced with Illumina HiSeq 4000.Comparing normoglycemic and diabetic subjects revealed 4404 significantly differentially expressed (DE) genes, which represents around 30% of all mapped genes in studied samples. For the comparison between type 2 diabetics and prediabetics, the number of DE genes was 4055 genes. Interestingly we found no significantly DE genes between normoglycemics and prediabetics. KEGG enrichment analysis revealed that DE pathways between diabetics vs. nondiabetics were enriched for pathways related to oxidative phosphorylation, thermogenesis, nonalcoholic fatty liver disease and neurological diseases, which share the same underlying mechanism: mitochondrial dysfunction.These results indicate that skeletal muscle contributes most to overt T2D, with a possible indication that the liver contributes most to early stages the disease development. Differences observed between type 2 diabetics and the two remaining groups, occurring primarily in oxidative phosphorylation and electron transport chain pathways suggests that mitochondrial dysfunction plays the predominant role in the pathogenesis of T2D. Disclosure L. Szczerbinski: None. M. Niemira: None. K. Szczerbinski: None. U. Puchta: None. E. Siewiec: None. A. Citko: None. J. Zapolska: None. M. Taylor: None. S. Larsen: None. M. Gorska: None. A. Kretowski: None.

NURR1 activation in skeletal muscle controls systemic energy homeostasis

Skeletal muscle plays a central role in the control of metabolism and exercise tolerance. Analysis of muscle enhancers activated after exercise in mice revealed the orphan nuclear receptor NURR1/NR4A2 as a prominent component of exercise-responsive enhancers. We show that exercise enhances the expression of NURR1, and transgenic overexpression of NURR1 in skeletal muscle enhances physical performance in mice. NURR1 expression in skeletal muscle is also sufficient to prevent hyperglycemia and hepatic steatosis, by enhancing muscle glucose uptake and storage as glycogen. Furthermore, treatment of obese mice with putative NURR1 agonists increases energy expenditure, improves glucose tolerance, and confers a lean phenotype, mimicking the effects of exercise. These findings identify a key role for NURR1 in governance of skeletal muscle glucose metabolism, and reveal a transcriptional link between exercise and metabolism. Our findings also identify NURR1 agonists as possible exercise mimetics with the potential to ameliorate obesity and other metabolic abnormalities.

SAT-180 MicroRNA Library Screening Identifies a Subset of Cooperative MicroRNAs That Affects Differentiation and Glucose Metabolism of Human Skeletal Muscle Cells

Skeletal muscle is a key target tissue for regulating whole body metabolism. Decreased muscle mass during the ageing process contributes to deteriorated metabolism and, next to obesity, is a major driver for the increasing prevalence of type 2 diabetes. Strategies to improve regeneration and glucose metabolism in skeletal muscle are therefore urgently needed. microRNAs (miRNAs) are important contributors to muscle formation and potential therapeutic targets, but the relevant miRNAs to improve muscle formation and insulin action are still poorly defined. Here, we aimed to develop strategies to identify miRNA networks during muscle regeneration irrespective of aberrant expression patterns in affected muscle tissues. Using miRNA library screening we determined that miRNA cooperativity controls differentiation in muscle cells that lack endogenous miRNAs after deletion of the RNA-binding protein DiGeorge syndrome critical region gene 8 (DGCR8). A group of only six miRNAs rescued morphological and gene expression changes in these knockout cells. Conversely, combinatorial inhibition of five of the six miRNAs (let7-5p, miR-29a-3p, miR-125b-5p, miR-199a-5p, and miR-221-3p) markedly enhanced differentiation in wildtype muscle cells from mice and humans. Improved muscle differentiation translated into improved insulin stimulated glycogen synthesis (+30%, p<0.05, Ant-5x versus control myotubes). Mechanistically, miRNA add-back and loss-of-function most significantly affected genes involved in focal adhesion signalling and antagonizing the subset of miRNAs in human skeletal muscle cells enhanced phosphorylation of p38 mitogen-activated protein kinase and AKT highlighting the importance of cues from the extracellular matrix for muscle formation and the regulation of glucose metabolism.

Targeting RalGAPα1 in skeletal muscle to simultaneously improve postprandial glucose and lipid control.

How insulin stimulates postprandial uptake of glucose and long-chain fatty acids (LCFAs) into skeletal muscle and the mechanisms by which these events are dampened in diet-induced obesity are incompletely understood. Here, we show that RalGAPα1 is a critical regulator of muscle insulin action and governs both glucose and lipid homeostasis. A high-fat diet increased RalGAPα1 protein but decreased its insulin-responsive Thr735-phosphorylation in skeletal muscle. A RalGAPα1Thr735Ala mutation impaired insulin-stimulated muscle assimilation of glucose and LCFAs and caused metabolic syndrome in mice. In contrast, skeletal muscle-specific deletion of RalGAPα1 improved postprandial glucose and lipid control. Mechanistically, these mutations of RalGAPα1 affected translocation of insulin-responsive glucose transporter GLUT4 and fatty acid translocase CD36 via RalA to affect glucose and lipid homeostasis. These data indicated RalGAPα1 as a dual-purpose target, for which we developed a peptide-blockade for improving muscle insulin sensitivity. Our findings have implications for drug discovery to combat metabolic disorders.

Geniposide Improves Glucose Homeostasis via Regulating FoxO1/PDK4 in Skeletal Muscle.

It is well-known that imbalance state of glucose metabolism triggers many metabolic diseases and glucose uptake in skeletal muscle accounts for 90% of body weight. Geniposide is one of the major natural bioactive constituents of gardenia fruit, and the regulation of geniposide on glucose metabolism in skeletal muscle has not yet been investigated. Here, on the basis of microarray analysis, we discovered that geinposide decreased pyruvate dehydrogenase kinase 4 (PDK4) expression in skeletal muscle of mice and subsequently found that geniposide inhibited the expressions of forkhead box O1 (FoxO1), PDK4, and phosphorylated pyruvate dehydrogenase in vitro and in vivo. Moreover, geniposide promoted a switch of slow-to-fast myofiber type and glucose utilization, suggesting that geniposide improved glucose homeostasis. In addition, mechanistic studies revealed that geniposide played above roles by regulating FoxO1/PDK4, which controlled fuel selection via pyruvate dehydrogenase. Meanwhile, effects of geniposide mentioned above could be reversed by FoxO1 overexpression. Together, these results establish that geniposide confers controls on fuel usage and glucose homeostasis through FoxO1/PDK4 in skeletal muscle.

BRL37344 stimulates GLUT4 translocation and glucose uptake in skeletal muscle via β2-adrenoceptors without causing classical receptor desensitization.

The type 2 diabetes epidemic makes it important to find insulin-independent ways to improve glucose homeostasis. This study examines the mechanisms activated by a dual β2-/β3-adrenoceptor agonist, BRL37344, to increase glucose uptake in skeletal muscle and its effects on glucose homeostasis in vivo. We measured the effect of BRL37344 on glucose uptake, glucose transporter 4 (GLUT4) translocation, cAMP levels, β2-adrenoceptor desensitization, β-arrestin recruitment, Akt, AMPK, and mammalian target of rapamycin (mTOR) phosphorylation using L6 skeletal muscle cells as a model. We further tested the ability of BRL37344 to modulate skeletal muscle glucose metabolism in animal models (glucose tolerance tests and in vivo and ex vivo skeletal muscle glucose uptake). In L6 cells, BRL37344 increased GLUT4 translocation and glucose uptake only by activation of β2-adrenoceptors, with a similar potency and efficacy to that of the nonselective β-adrenoceptor agonist isoprenaline, despite being a partial agonist with respect to cAMP generation. GLUT4 translocation occurred independently of Akt and AMPK phosphorylation but was dependent on mTORC2. Furthermore, in contrast to isoprenaline, BRL37344 did not promote agonist-mediated desensitization and failed to recruit β-arrestin1/2 to the β2-adrenoceptor. In conclusion, BRL37344 improved glucose tolerance and increased glucose uptake into skeletal muscle in vivo and ex vivo through a β2-adrenoceptor-mediated mechanism independently of Akt. BRL37344 was a partial agonist with respect to cAMP, but a full agonist for glucose uptake, and importantly did not cause classical receptor desensitization or internalization of the receptor.

Effects of Centella asiatica on skeletal muscle structure and key enzymes of glucose and glycogen metabolism in type 2 diabetic rats

BackgroundDysregulation of glucose and glycogen metabolism are crucial mechanisms implicated in type 2 diabetes mellitus (T2DM). Centella asiatica (L.) Urban (Apiaceae) has been utilized as a traditional medicine in Africa and Asia for centuries and is commercially available as a dietary supplement. AimWe explored for the first time, the possible efficacy of Centella asiatica (CA) extract in ameliorating T2DM-induced changes in key enzymes involved in glucose and glycogen metabolism in the rat skeletal muscle. MethodsDiabetic rats were orally treated with vehicle, CA (500 and 1000 mg/kg) or metformin (300 mg/kg) daily for 14 days. Skeletal muscle activities of hexokinase (HK), phosphofructokinase (PFK) and fructose 1,6-bisphosphatase (FBPase) were determined by spectrophotometric assays while those of glycogen synthase (GS) and glycogen phosphorylase (GP) were assayed radio-chemically. Histological examination of skeletal muscle was also performed. ResultsRats with induced T2DM had reduced activities of HK (25%), PFK (88%), and GS (38%) when compared to non-diabetic rats. Treatment of diabetic rats with CA500 increased the activities of PFK (7-fold), and FBPase (23%). Further, treatment of diabetic rats with CA1000 also increased the activities of GS (27%) and GP (50%) with little change in these parameters for diabetic rats treated with CA500. These effects probably led to the reduced blood glucose level and elevated skeletal muscle glycogen content observed in CA-treated rats relative to diabetic controls. Furthermore, CA treated rats had reduced the morphological damage of skeletal muscle fibres compared to the non-treated diabetic control rats. ConclusionOur findings strongly suggest that the anti-diabetic effects of CA in part target muscle glucose and glycogen metabolism and hence supporting its folkloric medical use as an anti-diabetic remedy.

Sex differences in the expression of lipid oxidation and glucose uptake genes in muscles of fasted mice

Fasting has become increasingly popular for treatment and prevention of obesity. Sex differences in the mechanisms of adaptation to fasting may contribute to choosing a therapeutic strategy for correction of metabolic disorders. Hepatokine fibroblast growth factor 21 (FGF21) is involved in the adaptation to fasting. Muscles are assumed to be the main energy-consuming tissue in the body, as muscle metabolism plays an important role in the adaptation to nutritional deficit. However, there is still little information on sex differences in muscle and FGF21 physiological response to fasting. Our aim was to find out whether there were sex differences in hormonal regulation and the expression of genes controlling glucose and lipid metabolism in skeletal muscles in response to fasting. We estimated the effect of 24-hour fasting on the expression of genes involved in lipid (Ucp3, Cpt1) and carbohydrate (Slc2a4) metabolism in muscles and evaluated changes in body weight and blood plasma levels of glucose, insulin, free fatty acids (FFA), adiponectin, and FGF21 in male and female C57BL/6J mice. None of the genes studied (Ucp3, Cpt1 and Slc2a4) showed sex-related changes at mRNA levels in control groups, but females exposed to fasting demonstrated a significant increase in the expression of all genes as compared to control. Fasting significantly decreased body weight and glucose blood plasma levels in animals of both sexes but exerted no effect on the levels of insulin or FFA. The adiponectin and FGF21 levels were increased in response to fasting, the increase in females being significant. We were first to show sex dimorphism in muscle gene expression and FGF21 blood level in response to fasting. In females, the greater increase in FGF21 and adiponectin blood levels was positively associated with the greater upregulation of lipid oxidation and glucose uptake gene expression.

Overexpression of Interleukin-15 exhibits improved glucose tolerance and promotes GLUT4 translocation via AMP-Activated protein kinase pathway in skeletal muscle

Skeletal muscle performs 80% of the glucose metabolism in the body. Improvement of insulin resistance and prevention of diabetes by habitual exercise is considered beneficial due to the improved glucose uptake in skeletal muscles. Investigation of the mechanism by which skeletal muscles regulate glucose uptake can contribute to the prevention and treatment of diabetes. Myokines are a kind of cytokine secreted from skeletal muscle, which are expected to regulate muscle metabolism. Interleukin-15 (IL-15) is one such myokine that has been reported to improve glucose metabolism in vitro, although the mechanism remains unclear. In this study, we examined the glucose metabolism of skeletal muscle-specific IL-15 transgenic mice (IL-15TG), and investigated how IL-15 affects glucose metabolism in skeletal muscles. Although High Fat Diet-fed IL-15TG did not exhibit obvious difference in intraperitoneal insulin tolerance test, they had less impaired glucose tolerance compared to wild-type C57BL/6. Phosphorylation of AMP-activated protein kinase (AMPK), Akt substrate of 160 kDa (AS160), tre-2/USP6, BUB2, and cdc16 domain family member 1 (TBC1D1), and translocation of Glucose transporter type 4 (GLUT4) were accelerated in the skeletal muscle of IL-15TG. Our study demonstrated that overexpression of IL-15 in skeletal muscle improves glucose metabolism in skeletal muscle via AMPK pathway. We report the first in-vivo study that describes the signaling pathway of IL-15 in muscle glucose metabolism, and thereby contributes to the elucidation of the regulatory mechanism of muscle glucose metabolism by myokines.

From the Literature

From the Literature

Novel metabolic disorders in skeletal muscle of Lipodystrophic Bscl2/Seipin deficient mice

Bscl2−/− mice recapitulate many of the major metabolic manifestations in Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) individuals, including lipodystrophy, hepatosteatosis, muscular hypertrophy, and insulin resistance. Metabolic defects in Bscl2−/− mice with regard to glucose and lipid metabolism in skeletal muscle have never been investigated. Here, we identified Bscl2−/− mice displayed reduced intramyocellular triglyceride (IMTG) content but increased glycogen storage predominantly in oxidative type I soleus muscle (SM). These changes were associated with increased incomplete fatty acid oxidation and glycogen synthesis. Interestingly, SM in Bscl2−/− mice demonstrated a fasting duration induced insulin sensitivity which was further confirmed by hyperinsulinemic-euglycemic clamp in SM of overnight fasted Bscl2−/− mice but reversed by raising circulating NEFA levels through intralipid infusion. Furthermore, mice with skeletal muscle-specific inactivation of BSCL2 manifested no changes in muscle deposition of lipids and glycogen, suggesting BSCL2 does not play a cell-autonomous role in muscle lipid and glucose homeostasis. Our study uncovers a novel link between muscle metabolic defects and insulin resistance, and underscores an important role of circulating NEFA in regulating oxidative muscle insulin signaling in BSCL2 lipodystrophy.

The decline of whole-body glucose metabolism in ovariectomized rats.

Age is a major risk factor for developing chronic diseases, including type 2 diabetes and osteoporosis. Emerging evidences suggest that the disorder of bone metabolism in osteoporosis is involved in the pathogenesis of glucose intolerance, insulin resistance and type 2 diabetes. However, their etiology and relative regulatory factors still remain elusive to clinicians and researchers. In this study, rats were divided into two groups: normal sham surgery control and ovariectomized (OVX) groups. We evaluated the global bone parameters, glucose metabolism, protein and gene expressions in both skeletal muscle and adipocytes. The present findings showed that the bone mineral density (BMD) and compression load of bone were markedly reduced in OVX rats as revealed by micro-CT, dual energy X-ray absorptiometry and bone biomechanics analysis. Besides, plasma estrogen, total alkaline phosphatase (TALP) and osteocalcin levels were significantly decreased in the OVX rats, but body weight, fat mass and plasma tartrate-resistant acid phosphatase (TRAP) and chemerin levels were significantly increased in the OVX rats. More interestingly, we found that p-AKT, p-P38MAPK, glucose transporter 4 (GLUT4) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) contents as well as GLUT4 and PGC-1α mRNA expression were significantly decreased in skeletal muscle and adipocytes of OVX rats. In conclusion, our results indicated that whole-body glucose metabolism and glucose intolerance in OVX rats was degressive, suggesting there was a novel link between osteoporosis and whole body glucose homeostasis, which are controlled by the P38MAPK/PGC-1α/GLUT4 signaling pathway.

Sustained maternal inflammation during the early third trimester yields fetal adaptations that impair subsequent skeletal muscle growth and glucose metabolism in sheep.

Sustained maternal inflammation during the early third trimester yields fetal adaptations that impair subsequent skeletal muscle growth and glucose metabolism in sheep.

The Flavonoid Kaempferol Ameliorates Streptozotocin-Induced Diabetes by Suppressing Hepatic Glucose Production.

In diabetes mellitus, the excessive rate of glucose production from the liver is considered a primary contributor for the development of hyperglycemia, in particular, fasting hyperglycemia. In this study, we investigated whether kaempferol, a flavonol present in several medicinal herbs and foods, can be used to ameliorate diabetes in an animal model of insulin deficiency and further explored the mechanism underlying the anti-diabetic effect of this flavonol. We demonstrate that oral administration of kaempferol (50 mg/kg/day) to streptozotocin-induced diabetic mice significantly improved hyperglycemia and reduced the incidence of overt diabetes from 100% to 77.8%. This outcome was accompanied by a reduction in hepatic glucose production and an increase in glucose oxidation in the muscle of the diabetic mice, whereas body weight, calorie intake, body composition, and plasma insulin and glucagon levels were not altered. Consistently, treatment with kaempferol restored hexokinase activity in the liver and skeletal muscle of diabetic mice while suppressed hepatic pyruvate carboxylase activity and gluconeogenesis. These results suggest that kaempferol may exert antidiabetic action via promoting glucose metabolism in skeletal muscle and inhibiting gluconeogenesis in the liver.

Exercise improves glucose uptake in murine myotubes through the AMPKα2-mediated induction of Sestrins

Exercise training increases insulin sensitivity. Over the past decades, considerable progress has been made in understanding the molecular basis for this important effect of physical exercise. However, the underlying mechanism is still not fully described. Recent studies have revealed that the stress responsive protein family Sestrins (SESNs) may play an important role in improving insulin sensitivity of skeletal muscle under exercise training. In this study, we aim to better understand the relationship between SESNs and AMPK in response to exercise training and the possible mechanism by which SESNs mediate glucose metabolism. We used wild type, AMPKα2+/− and AMPKα2−/− C57BL/6 mice to reveal the pathway by which 6 weeks of exercise training induced SESNs. We explored the mechanism through which SESNs regulated glucose metabolism in vitro by overexpressing or inhibiting SESNs, and inhibiting AMPK or autophagy in myotubes. We found that a 6-week exercise training regime improved oxidative metabolism, activated the insulin signaling pathway and increased the level of SESN2 and SESN3 in an AMPKα2-dependent manner. Overexpression of SESN3 or SESN2 and SESN3 together increased glucose uptake, activated the insulin signaling pathway, and promoted GLUT4 translocation in myotubes. Although inhibition of SESNs had no effect on glucose uptake, SESNs could reverse reduced glucose uptake following autophagy inhibition, and may be downstream effectors of AMPK responses in myotubes. Taken together our data show that SESNs are induced by AMPKα2 after exercise training, and SESNs, specifically SESN3, play a key role in exercise training-mediated glucose metabolism in skeletal muscle.

Pharmacologic Uncoupling of Skeletal Muscle Mitochondria Promotes Glucose Metabolism

Mitochondrial uncoupling was one of the earliest pharmacologic approaches to the treatment of obesity-related diseases. However, low mitochondrial specificity and negative off-target effects limited the viability of such agents. BAM15 is a small molecule recently identified for its potent ability to uncouple mitochondria. Thus, the purpose of this investigation was to explore the physiological effects of BAM15 on skeletal muscle mitochondrial function and glucose metabolism. C2C12 myotubes were incubated with either vehicle or BAM15 at varying concentrations for 16 hours. Cell viability was assessed by detection of dehydrogenase activity. Cytotoxicity was measured by a Caspase 3/7 activity assay. Glucose uptake was measured using [3H]-2-deoxy-D-glucose in the presence and absence of insulin. Oxygen consumption rates were measured using an XF24 extracellular flux analyzer. Cells were harvested for the assessment of plasma membrane GLUT4 and protein signaling via Western blot. Cells treated with BAM15 were viable up to 100 μM, and lacked toxicity up to 50 μM, compared to vehicle. BAM15 significantly increased glucose uptake (P&amp;lt;0.05) at concentrations as low as 6.25 μM. Concentrations of 25 μM and above exhibited a 2-4 fold greater glucose uptake than insulin (P&amp;lt;0.05), which saturated at 50 μM. BAM15 significantly increased basal oxygen consumption (P&amp;lt;0.05), while markedly reducing coupling efficiency (P&amp;lt;0.05). BAM15 upregulated primary energy homeostasis pathways via activation of AKT (t3and s473), AS160 (t642), and AMPK (t172). Additionally, BAM15 increased plasma membrane GLUT4 translocation (P&amp;lt;0.05). BAM15 is a pharmacologically active compound with low toxicity and mitochondrial specificity capable of inducing glucose metabolism in skeletal muscle. These data provide compelling evidence for future investigation of BAM15 as a potential treatment for diabetes and other obesity-related metabolic diseases. Disclosure M.E. Hull: None. C.L. Axelrod: None. K.M. Fitzgerald: None. J. Sacks: None. J.P. Kirwan: None.

IMG-1 Lowers Insulin Resistance by Decreasing Hepatic Glucose Production in a DIO Mouse Clamp Test

IMG-1 is a novel therapeutic compound for the treatment of diabetes. IMG-1 has been shown to successfully treat both type 1 mice and rats (STZ models) and type 2 ZDF rats. To test how IMG-1 is able to treat type II diabetes, diet-Induced Obese (DIO) C57BL/6J mice were used in a hyperinsulinemic-euglycemic clamp assay. The hyperinsulinemic-euglycemic clamp is the gold-standard method to assess insulin sensitivity. The euglycemic clamp is widely used in clinics and laboratories to measure insulin action on glucose utilization in humans and animals for clinical and basic science research. Sixteen DIO C57BL/6J mice underwent a 2-hour hyperinsulinemic-euglycemic clamping to assess insulin action and glucose metabolism in IMG-1 treated (2µg IMG-1 administered IV via tail vein 48 and 24hours prior to the clamp test, n=8) or PBS treated animals (n=8). IMG-1 treated animals had significantly higher steady-state glucose infusion rates during clamping than PBS treated animals, indicating that IMG-1 is able to decrease insulin resistance in DIO mice. IMG-1 did not affect whole-body glucose turnover, glycolysis or glycogen synthesis in any of the treated animals. Glucose metabolism in skeletal muscle and adipose tissue was not significantly different in either IMG-1 or PBS treated animals during the clamp assay. However, Hepatic Glucose Production (HGP) was dramatically suppressed in all animals treated with IMG-1 (a decrease from 3.mg/kg/m to -6.16 mg/kg/m). Furthermore, hepatic insulin action (the percent suppression of HGP) was increased in all IMG-1 treated animals&amp;#x2028;during the hyperinsulinemic-euglycemic clamp (from 70.9 control to 99.7 IMG-1). IMG-1 is a novel compound for the treatment of diabetes. These results show that IMG-1 decreases insulin resistance in a type 2 diabetic mouse model by suppressing HGP and increasing hepatic insulin action. Disclosure J.B. Pollett: Employee; Self; Imagine Pharma. H. Noh: None. J.K. Kim: None. N. Thai: Board Member; Self; Imagine Pharma.

Combination of Canagliflozin and Exercise Training Leads to Lipid-Dependent Energy Expenditure in Skeletal Muscle in Obese Diabetic Mice

Background and Aim: Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert multiple metabolic effects. Exercise training is a robust treatment of obesity and diabetes, but the effect of SGLT2 inhibitors on exercise training is unclear. We investigated the association between canagliflozin (CAN) and training effects on skeletal muscle and liver in obese diabetic mice. Method: Male mice loaded with a high-fat diet for 4 weeks were housed in a normal cage (sedentary; sed) or wheel cage (WCR). A total of 0.03%w/w CAN was administrated for 2 weeks. Glucose and lipid metabolism of skeletal muscle (gastrocnemius) was analyzed and compared among 4 groups (control/sed, control/WCR, CAN/sed, and CAN/WCR). Results: Body weight in control/WCR and CAN/sed mice was significantly lower compared with that in control/sed mice, and further weight loss was observed in CAN/WCR mice. There was no difference in running distance between control/WCR and CAN/WCR mice. Control/WCR mice showed lower blood glucose levels than did control/sed mice (200.0±4.2 vs. 231.9±8.7 mg/dL, p=0.01). CAN decreased glucose levels, but there was no difference between CAN/sed (118.9±6.29 mg/dL) and CAN/WCR mice (113.6±4.48 mg/dL). GLUT1 and GLUT4 mRNA levels in skeletal muscle in CAN/sed and CAN/WCR mice were significantly lower than those in control/sed mice. Levels of mRNA of CD36 (× 1.26 in CAN/sed and × 1.31 in CAN/WCR mice, both p&amp;lt;0.05) and CPT1b (× 1.09 in CAN/sed and × 1.21 in CAN/WCR mice, both p&amp;lt;0.05) were significantly higher than those in control/sed mice. CPT1b mRNA levels in CAN/WCR mice were significantly higher than those in CAN/sed mice (p&amp;lt;0.05). Discussion: CAN promoted transition from glucose to lipid-dependent energy metabolism in skeletal muscle and this effect might have been enhanced by concomitant exercise. Conclusion: The combination of CAN and exercise may be effective for weight loss in obesity by an increase in lipid energy expenditure. Disclosure K. Tanaka: Research Support; Self; Mitsubishi Tanabe Pharma Corporation. H. Takahashi: Research Support; Self; Mitsubishi Tanabe Pharma Corporation. K. Sasaki: Employee; Self; Mitsubishi Tanabe Pharma Corporation. K. Inoue: None. Y. Matsuda: None. Y. Eguchi: None. K. Anzai: Research Support; Self; Mitsubishi Tanabe Pharma Corporation, Sysmex Corporation.

Profiling Mitochondrial Quality Control in Human Myotubes Derived from Severely Obese Non‐diabetic and Type 2 Diabetic Patients

Mitochondrial networks are maintained via integration of mitochondrial quality control processes, including biogenesis, fusion/fission dynamics and mitophagy. There is evidence to suggest that mitochondrial quality control plays a critical role in the regulation of mitochondrial function and glucose metabolism in skeletal muscle, and disruptions of these processes accompany the presence of skeletal muscle insulin resistance and type 2 diabetes (T2D). However, whether disruptions of mitochondrial quality control processes are retained at the muscle cell level is largely unknown. The purpose of this study was to determine whether the expression of proteins involved in mitochondrial quality control processes were dysregulated in primary human myotubes derived from type 2 diabetic patients. Primary human skeletal muscle cells were isolated from muscle biopsies obtained from eight severely obese, non‐diabetic subjects (BMI = 52.4 kg/m2, fasting glucose = 98.9 mg/dl) and eight severely obese, type 2 diabetics (BMI = 49 kg/m2, fasting glucose 132.3 mg/dl), and were differentiated to myotubes. On day 7 of differentiation, myotubes were harvested for immunoblot analysis to assess the expression of proteins involved in each of the four mitochondrial quality control processes. Mitochondrial fusion protein expression (Optic Atrophy Protein 1 (Opa1) and Mitofusin 1 (Mfn1)) were significantly lower in myotubes derived from type 2 diabetic patients in comparison to the BMI‐matched, non‐diabetic subjects (0.038 ± 0.003 vs. 0.024 ± 0.002 and 0.440 ± 0.042 vs. 0.320 ± 0.038, respectively, P &lt; 0.05). In addition, expression of the mitophagic protein Parkin was significantly lower in primary myotubes derived from type 2 diabetic patients (0.0028 ± 0.0003 vs. 0.0018 ± 0.0002, P &lt; 0.05). No significant differences were found in expression of other fusion or mitophagy proteins (Mitofusin 2 (Mfn2), or PTEN‐Induced Putative Kinase 1 (PINK1)), or proteins related to mitochondrial fission (dynamin related protein 1 (Drp1) and mitochondrial fission 1 protein (Fis1)), and biogenesis (PGC‐1α). These data suggest that mitochondrial quality control is dysregulated in primary myotubes derived from type 2 diabetic patients in a manner that favors fission over fusion.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.